SCHEMBL1764965

SCHEMBL1764965

O=C(O)c1cc(-c2cccc(F)c2)n(-c2ccc(F)c(Cl)c2)n1

nearest known ligand 0.65

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
RPA1 P27694 11/20 0.65
PPP1CA P62136 3/20 0.61
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
ATM Q13315 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.54
MARS1 P56192 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765048 0.89 KMT2A (0.75) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1765068 0.89 PPP1CA (0.71) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1526212 0.87 RPA1 (0.61) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1764940 0.87 RPA1 (0.60) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1765454 0.87 RPA1 (0.65) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1764873 0.86 RPA1 (0.64) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1764957 0.86 PPP1CA (0.75) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1764890 0.85 KMT2A (0.82) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL15004258 0.85 RPA1 (0.59) RPA1PPP1CAKMT2AMEN1ATM
SCHEMBL1765503 0.85 RPA1 (0.61) RPA1PPP1CAKMT2AMEN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
CN-101977908-A (pyrazolyl carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases AICURIS GMBH & CO KG 2011-02-16 CN disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO RPA1 3978/4885PPP1CA 1664/4885KMT2A 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.